Evidence map›Paper›PMID 42463821›Full record

ArticleScientific reports2026

Assessment of potential nephrotoxicity biomarkers after [

Charlotte Ytterbrink, Daniella Pettersson, Emman Shubbar, Khalil Helou, Martin E Johansson, Eva Forssell-Aronsson

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Charlotte YtterbrinkDepartment of Medical Radiation Sciences, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
Daniella PetterssonDepartment of Medical Radiation Sciences, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
Emman ShubbarDepartment of Medical Radiation Sciences, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
Khalil HelouSahlgrenska Center for Cancer Research, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
Martin E JohanssonSahlgrenska Center for Cancer Research, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
Eva Forssell-AronssonDepartment of Medical Radiation Sciences, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden. eva.forssell_aronsson@radfys.gu.se.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Patients with neuroendocrine tumours may receive higher total amount of [

Indexed as

Alpha-GlobulinsKidneyKidney DiseasesLutetiumOctreotideOrganometallic CompoundsRadioisotopesRadiopharmaceuticalsAnimalsBiomarkersCreatinineCystatin CFemaleMaleMiceRetinol-Binding Proteins, Plasma177Lu-octreotatealpha-1-microglobulinAlpha-GlobulinsBiomarkersCreatinineCystatin CLutetiumOctreotideOrganometallic CompoundsRadioisotopesRadiopharmaceuticalsRetinol-Binding Proteins, PlasmaAlpha-1-microglobulinCystatin CKidney toxicityKIM-1Radionuclide therapyRBP4

Identifiers

PMID42463821
PMCPMC13376859

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.